Vyne Therapeutics Inc. is a biopharmaceutical firm headquartered in Bridgewater, New Jersey, focused on developing innovative therapies for dermatological disorders. Leveraging its proprietary technology and therapeutic platforms, Vyne addresses critical unmet medical needs in skin diseases to enhance treatment outcomes and patient quality of life. With a strong pipeline of developing candidates, the company is well-positioned to significantly impact the biopharmaceutical landscape, offering transformative solutions that could reshape dermatological care. Show more

Location: 685 ROUTE 202/206 N, BRIDGEWATER, NJ, UNITED STATES, 08807, Bridgewater, NJ, 08807, USA | Website: https://vynetherapeutics.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE

Market Cap

18.84M

52 Wk Range

$0.28 - $2.94

Previous Close

$0.57

Open

$0.55

Volume

350,152

Day Range

$0.55 - $0.58

Enterprise Value

-20.77M

Cash

19.35M

Avg Qtr Burn

-7.096M

Insider Ownership

4.31%

Institutional Own.

14.67%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Amzeeq (minocycline) Details Acne vulgaris	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Zilxi (Minocycline) Details Rosacea	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
VYN202 Details Immune-mediated & inflammatory diseases; hematologic cancers; moderate-to-severe plaque psoriasis	Phase 1b Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
FCD105 (minocycline & adapalene) Details Acne vulgaris	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Repibresib (VYN201) Details Vitiligo	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
FMX114 (tofacitinib and fingolimod) Details Atopic dermatitis	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.